Trials / Terminated
TerminatedNCT03370861
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Immunotherapy Multi-omics Specimen Protocol A
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
Detailed description
Details will be available upon publication.
Conditions
- Autoimmunity
- Melanoma
- Merkel Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
- Basal Cell Carcinoma
- Skin Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Immunotherapy | Medications that increase the activity of the immune system. |
Timeline
- Start date
- 2017-11-08
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2017-12-12
- Last updated
- 2024-09-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03370861. Inclusion in this directory is not an endorsement.